Adicet Bio Inc (ACET)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$9.59+1.70%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ACET
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 17.6% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name has erratic recent earnings surprises and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
ACET — capital allocation — Unregistered Sales of Equity Securities
Dated 2026-04-28
Unregistered Sales of Equity Securities. On April 27, 2026, Adicet Bio, Inc. (the Company) entered into an exchange agreement with RA Capital Management, L.P. and RA Capital Healthcare Fund, L.P. (together, RA Capital) pursuant to which RA Capital exchanged 250,000 shares of the Company’s common stock, par value $0.0001 per share (Common Stock) for a pre-funded warrant (the Pre-Funded Warrant) to acquire 250,000 shares of Common Stock. The Pre-Funded Warrant has an exercise price of $0.0001 p…
Why it matters: Positive FDA feedback will support the design of a pivotal trial for prula-cel. This could enhance the regulatory path for Adicet.
Supportive ifThe FDA gave good feedback on the trial design for prula-cel.
Worry ifThe FDA says big changes are needed for the trial design.
Why it matters: This update will provide data from 22 patients with lupus nephritis and SLE. It is a key milestone for Adicet's clinical development.
Supportive ifTopline results from the Phase 1 trial are reported as anticipated in Q3 2026.
Worry ifThe update is delayed or does not include data from at least 22 patients.
Why it matters: Monitoring cash levels is crucial as Adicet aims to fund operations into 2027. A significant drop could raise concerns.
Worry ifCash and short-term investments are more than $100 million.
Less concerning ifCash position falls below $100 million.
Why it matters: How the company uses its money can affect investor trust and stock value.
Watch forManagement has a clear plan for using money from recent sales to support growth.
Also watch forManagement provides no clear plan for the use of proceeds from the equity sales.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$225 on $10,000 · ±2.2% | How much price usually moves either way. |
| Bad day | $718 loss on $10,000 · 7.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,328 loss on $10,000 · 63.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Progress in these therapies is critical for the company's growth and future revenue.
Supportive ifNew results from clinical trials or partnerships in gamma delta T cell therapies were shared.
Worry ifNo updates or delays in clinical trials for gamma delta T cell therapies.
Why it matters: Watching cash burn is key for Adicet to fund operations into 2027. It shows financial health.
Worry ifCash, cash equivalents, and short-term investments stay steady or go up.
Less concerning ifCash reserves are dropping a lot, showing higher cash burn than expected.
Why it matters: Updates on the CAR-T platform could show progress in Adicet's technology. Good news may draw investor interest and help growth.
Watch forAnnouncement of major progress or good results from the in vivo CAR-T platform.
Also watch forNo updates or bad news about the CAR-T platform.
Why it matters: This filing is important for Adicet's treatment of advanced prostate cancer. It shows progress in their plans.
Supportive ifAdicet submitted a filing for ADI-212 as planned in Q3 2026.
Worry ifThe filing is delayed beyond Q3 2026.
Why it matters: FDA clearance is crucial for starting the Phase 1 trial of ADI-212. This could lead to new treatment options for mCRPC.
Supportive ifFDA grants clearance for the IND application for ADI-212.
Worry ifFDA denies or delays the IND application for ADI-212.
Why it matters: Topline results will show how well prula-cel works in lupus patients. This data is key for future trials.
Supportive ifThe prula-cel study shows strong results. It is effective and safe.
Worry ifThe results show no clear benefits. Prula-cel is not effective or safe.
Why it matters: Details about the trial design will help guide prula-cel's use in lupus treatment.
Watch forManagement gives an update on the trial design for prula-cel.
Also watch forNo new details are given about the trial design for prula-cel.